TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

~ Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021 ~ Multiple Ascending Dose (MAD) Study Demonstrates Inhaled Tacrolimus Inhalation Powder Achieves Blood Levels Sufficient for Efficacious Immunosuppression ~ Formation of Scientific Advisory Board to Enable Continued Innovation and Clinical Development ~ Partnerships with Pharma, Academic Institutions and Government Continue to Advance

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here